Business Description
Roivant Sciences Ltd
ISIN : BMG762791017
Share Class Description:
ROIV: Ordinary SharesDescription
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 102.2 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 12.12 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 62.4 | |||||
| 3-Year EPS without NRI Growth Rate | -15.6 | |||||
| 3-Year FCF Growth Rate | -4.2 | |||||
| 3-Year Book Growth Rate | 41.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.55 | |||||
| 9-Day RSI | 41.36 | |||||
| 14-Day RSI | 46.37 | |||||
| 3-1 Month Momentum % | -3.96 | |||||
| 6-1 Month Momentum % | 7.48 | |||||
| 12-1 Month Momentum % | 12.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.43 | |||||
| Quick Ratio | 10.43 | |||||
| Cash Ratio | 9.68 | |||||
| Days Inventory | 496.59 | |||||
| Days Sales Outstanding | 132.69 | |||||
| Days Payable | 1101.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | 10.02 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.22 | |||||
| Operating Margin % | -895.8 | |||||
| Net Margin % | 3827.42 | |||||
| FCF Margin % | -621.6 | |||||
| ROE % | 101.93 | |||||
| ROA % | 82.08 | |||||
| ROIC % | -163.53 | |||||
| 3-Year ROIIC % | -1499.39 | |||||
| ROC (Joel Greenblatt) % | 7120.15 | |||||
| ROCE % | 84.05 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2.14 | |||||
| PS Ratio | 78.13 | |||||
| PB Ratio | 1.72 | |||||
| Price-to-Tangible-Book | 1.72 | |||||
| EV-to-EBIT | 0.74 | |||||
| EV-to-EBITDA | 0.74 | |||||
| EV-to-Revenue | 27.7 | |||||
| EV-to-Forward-Revenue | 42.4 | |||||
| EV-to-FCF | -4.46 | |||||
| Price-to-GF-Value | 0.72 | |||||
| Price-to-Net-Current-Asset-Value | 1.84 | |||||
| Price-to-Net-Cash | 2.01 | |||||
| Earnings Yield (Greenblatt) % | 135.14 | |||||
| FCF Yield % | -8.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ROIV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roivant Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 125.677 | ||
| EPS (TTM) ($) | 5.65 | ||
| Beta | 1.49 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.13 | ||
| Volatility % | 32.08 | ||
| 14-Day RSI | 46.37 | ||
| 14-Day ATR ($) | 0.309002 | ||
| 20-Day SMA ($) | 12.058 | ||
| 12-1 Month Momentum % | 12.46 | ||
| 52-Week Range ($) | 9.69 - 13.055 | ||
| Shares Outstanding (Mil) | 727.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roivant Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roivant Sciences Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Roivant Sciences Ltd Frequently Asked Questions
What is Roivant Sciences Ltd(ROIV)'s stock price today?
The current price of ROIV is $11.88. The 52 week high of ROIV is $13.06 and 52 week low is $9.69.
When is next earnings date of Roivant Sciences Ltd(ROIV)?
The next earnings date of Roivant Sciences Ltd(ROIV) is 2025-02-13 Est..
Does Roivant Sciences Ltd(ROIV) pay dividends? If so, how much?
Roivant Sciences Ltd(ROIV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers